Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589028 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2TSHRMAPTKMT2ANPSR1 | |
| SCHEMBL11404096 | 0.79 | FAAH (0.43) | SMN1; SMN2TSHRMAPTKMT2ANPSR1 | |
| SCHEMBL5138597 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRMAPTKMT2ANPSR1 | |
| SCHEMBL12669780 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRMAPTKMT2ANPSR1 | |
| SCHEMBL8060600 | 0.77 | TSHR (0.56) | SMN1; SMN2TSHRMAPTKMT2ANPSR1 | |
| SCHEMBL252121 | 0.77 | TSHR (0.56) | SMN1; SMN2TSHRMAPTKMT2ANPSR1 | |
| SCHEMBL17859667 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRMAPTKMT2ANPSR1 | |
| SCHEMBL17859666 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRMAPTKMT2ANPSR1 | |
| SCHEMBL19512283 | 0.74 | HRH3 (0.35) | — | |
| SCHEMBL11367872 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076503-B1 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-7973012-B2 | C-phenyl glycitol compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | SLC5A1, SLC5A2, SLC2A1 | SMN1; SMN2 4544/4885TSHR 2437/4885MAPT 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.